Asia Pacific Hemophilia Market Size & Outlook, 2022-2030
Asia Pacific hemophilia market, 2018-2030 (US$M)
Related Markets
Asia Pacific hemophilia market highlights
- The Asia Pacific hemophilia market generated a revenue of USD 2,400.3 million in 2022.
- The market is expected to grow at a CAGR of 7% from 2023 to 2030.
- In terms of segment, hemophilia a was the largest revenue generating type in 2022.
- Hemophilia A is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 2,400.3 million |
| Market revenue in 2030 | USD 4,131.6 million |
| Growth rate | 7% (CAGR from 2022 to 2030) |
| Largest segment | Hemophilia a |
| Fastest growing segment | Hemophilia A |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hemophilia A, Hemophilia B |
| Key market players worldwide | Takeda Pharmaceutical Co Ltd, CSL Ltd, Pfizer Inc, Bayer AG, Biomarin Pharmaceutical Inc, Roche Holding AG ADR, Sanofi SA, Novo Nordisk A/S ADR, Spark Therapeutics, Octapharma AG |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 19.0% of the global hemophilia market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 5,372.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemophilia Market Scope
Hemophilia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific hemophilia market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemophilia market will help companies and investors design strategic landscapes.
Hemophilia a was the largest segment with a revenue share of 74.17% in 2022. Horizon Databook has segmented the Asia Pacific hemophilia market based on hemophilia a, hemophilia b covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Hemophilia Type Outlook (Revenue, USD Million, 2018-2030)
- Hemophilia A
- Hemophilia B
- Others
- Asia Pacific Hemophilia Treatment Type Outlook (Revenue, USD Million, 2018-2030)
- On-demand
- Cure
- Prophylaxis
- Asia Pacific Hemophilia Therapy Outlook (Revenue, USD Million, 2018-2030)
- Factor Replacement Therapy
- Plasma-derived Factor Concentrates
- Factor VIII
- Factor IX
- Plasma-derived Factor Concentrates
- Recombinant Factor Concentrates
- Factor VIII RFC
- Factor VII
- Factor IX RFC
- Desmopressin & Fibrin Sealants
- Gene Therapy & Monoclonal Antibodies
- Factor Replacement Therapy
- Asia Pacific Hemophilia Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Specialty Pharmacies
Reasons to subscribe to Asia Pacific hemophilia market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific hemophilia market databook
-
Our clientele includes a mix of hemophilia market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific hemophilia market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific hemophilia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific hemophilia market size, by country, 2018-2030 (US$M)
Asia Pacific Hemophilia Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
